CORONARY ARTERY DISEASE AND CARDIOVASCULAR OUTCOMES IN HEART FAILURE: INSIGHTS FROM THE VERICIGUAT GLOBAL STUDY IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL
Paul W. Armstrong(Canadian VIGOUR Centre), Kevin Anstrom(PragmatIC (United Kingdom)), Amanda Stebbins(University of Alberta), Basil S. Lewis(Technion – Israel Institute of Technology), Burkert Pieske(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Imran Bin Zainal Abidin(University of Alberta), Piotr Ponikowski(Wroclaw Medical University), Javed Butler(Jackson Memorial Hospital), Joerg Koglin(Ludwig-Maximilians-Universität München), Clara Inés Saldarriaga Giraldo(University of Alberta), Carolyn S.P. Lam(University of Glasgow), Adrían V. Hernández(University of Connecticut), Adriaan A. Voors(University Medical Center Groningen), Dan Atar, Lothar Roessig(Bayer (Germany)), Christopher M. O’Connor(Inova Health System), Justin A. Ezekowitz(University of Alberta)
Cited by 0
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k